Biotechnology Sector

In the contemporary healthcare landscape, the importance of psychological resilience among oncology nurses cannot be overstated. The role of these healthcare professionals extends far beyond administering treatments; they are pivotal in providing emotional support to patients grappling with cancer. In a groundbreaking cross-sectional study led by Özcan, Özkaraman, and Özgenel, the authors delve into the

Chronic hepatitis B virus (HBV) infection remains a leading cause of liver-related morbidity and mortality worldwide. Recent advancements in proteomics have opened new avenues for understanding the intricate biological interactions between HBV and non-alcoholic fatty liver disease (NAFLD), a condition increasingly recognized as pivotal in shaping liver disease profiles among patients with chronic hepatitis. A

In a remarkable stride toward biodiversity understanding, the discovery of Cymbalaria muralis (commonly known as wall pennywort) in the Kashmir Himalaya marks a significant academic achievement, as reported in a recent publication in the journal Discover Plants. This chasmophyte, belonging to the Plantaginaceae family, has been overlooked in this region until now. The research team,

In a groundbreaking study, researchers have identified a novel therapeutic application for Pyrroloquinoline quinone (PQQ), a naturally occurring compound known for its antioxidant properties. The research team, led by Geng et al., focused on the implications of PQQ for addressing the challenges posed by senescent osteoclasts—cells that are pivotal in bone resorption and frequently implicated

A groundbreaking advancement in prostate cancer treatment offers new hope to men whose disease returns after initial attempts at surgery or radiation therapy. The latest clinical trials unveil a powerful new drug regimen capable of drastically reducing mortality risk, marking a significant milestone in the battle against high-risk biochemically recurrent prostate cancer. For decades, the

In an era where sleep is increasingly recognized for its pivotal role in overall health and well-being, researchers are striving to enhance understanding and monitoring of sleep processes. The landmark study led by Aktaruzzaman and Everett encapsulates this initiative through the development of an advanced, non-invasive methodology for detecting sleep stages. Their research uniquely merges

A groundbreaking study published in “Biology of Sex Differences” highlights the intricate dynamics of energy demand variations between male and female subjects during the preplaque stage of Alzheimer’s disease, utilizing a transgenic mouse model that mirrors human Alzheimer’s pathology. This pivotal research led by a team of scientists, including Ren Sun, Lisa K. Zimbalski, and

In a groundbreaking advancement in the treatment of aggressive breast cancers, researchers have unveiled promising results from the ASCENT-03 trial, identifying sacituzumab govitecan as a transformative therapy for patients battling triple-negative breast cancer (TNBC) who are unsuitable candidates for immune checkpoint inhibitor therapy. This compelling evidence, emerging from a global phase 3 clinical study led

In recent years, the integration of autistic individuals into the workforce has garnered increasing attention from researchers, employers, and advocates alike. A notable study led by Athamanah, White, and Frala, published in the Journal of Autism and Developmental Disorders, examines the experiences of employers who have hired autistic employees in competitive integrated employment settings. This

In the realm of healthcare, the transition from academia to a professional setting can often be formidable, particularly for novice nurses. The intricacies of workplace culture, expectations, and the demand for adaptability can pose substantial challenges. A cross-sectional study conducted by Y. Nagano and Y. Hosoda sheds light on a critical yet often understated aspect

Recent advancements in spatial proteomics have opened new avenues for understanding the biological mechanisms behind aging, particularly in the renal tubulointerstitium—a crucial component of the kidney. Researchers have embarked on a groundbreaking study that reveals how aging leads to significant alterations in this region, which is vital for maintaining renal function and overall health. By

Recent advancements in cellular biology have illuminated the transformative potential of targeting specific RNA molecules to rejuvenate senescent cells. In a groundbreaking study, researchers led by Wang et al. have explored the roles of PURPL RNA in reprogramming senescent cells through epigenetic mechanisms. Their findings, published in the Journal of Translational Medicine, suggest that manipulating

In a transformative study published in Scientific Reports, researchers have embarked on an ambitious project to restore and generate intricate Kraak porcelain decorative patterns using advanced generative artificial intelligence techniques. Kraak porcelain, known for its exquisite craftsmanship and rich history, has captivated art lovers and collectors for centuries. The study revolves around the development of

Recent advances in neuroscience have illuminated the intricate relationships between genetic expression, behavior, and emotional health. One particularly compelling study, authored by Senserrich et al., has delved deeply into the sex differences influencing anxiety and depression-like behaviors, centering its focus on a key player in the neurobiological landscape: matrix metalloproteinase-9 (MMP-9). This enzyme, known for

In a groundbreaking study, researchers have delved into the intricacies of language switching behaviors among multilingual autistic and non-autistic adults. The exploration, conducted by Crockford, Gibson, and Katsos, uncovers critical insights into how these two groups navigate their linguistic environments. Parallels drawn in this research could have profound implications for our understanding of cognitive processing

Nursing interventions are of paramount importance in the continuous battle against cardiovascular disease (CVD), a leading cause of mortality globally. The recent narrative review conducted by Garea and Díaz sheds light on evidence-based strategies that nurses can implement to mitigate the risk of cardiovascular complications. This comprehensive exploration into nursing interventions is more than just

In a groundbreaking study set to reshape our understanding of the intricate relationship between COVID-19 and its long-term consequences, a team of researchers led by M.V. Rajan, V. Sharma, and N. Upadhyay has unveiled compelling data derived from serum proteomics. This innovative approach looks beyond the immediate viral threat posed by SARS-CoV-2 to identify biomarkers

Recent research has unveiled critical insights into the biological mechanisms underlying retroperitoneal liposarcoma (RPLS), a rare and aggressive form of cancer originating from fat tissue in the retroperitoneum. In a pioneering study conducted by Zhang et al., it has been demonstrated that the aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) plays a significant role in

In the realm of public health, the interplay between chronic disease management and social factors has garnered significant attention in recent years. A pivotal study titled “Association Between Diabetes Management Behaviors and State-Level Social Vulnerability: A Cross-sectional Study,” recently brought to light the complex intersection of diabetes management and social vulnerability. In a world where

Cancer remains one of the most formidable challenges in global health, claiming millions of lives annually and placing immense strain on healthcare systems worldwide. The disease’s complexity is deeply rooted in its genetic basis, where mutations and alterations at various molecular levels result in malignant transformation. Among the most promising avenues for combating cancer is

Europe’s leading cancer conference may be swimming in ADC data, but AstraZeneca remains convinced its in-house pipeline sets the pharma apart.

Tubulis’ next-generation ADC has been tied to an overall response rate of 59% as the German biotech tastes its first clinical success.

Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash conditions for an acquisition inked back in August.

As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. The post NLS Days: How do things look for biotech in Sweden?  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a wasting syndrome.

Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring a 75% objective response rate (ORR) in patients with advanced melanoma after two years. But the trial enrolled far fewer patients than originally planned and did not evaluate its primary endpoint.

Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% in a specific cohort of a phase 3 trial.

For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated-virus-based therapy designed to treat a rare neurodevelopmental condition.

Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.

Hansoh has announced a deal with Roche worth up to $1.45 billion biobucks to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental ADC. At the same time, Rani has secured an agreement worth up to $1.09 billion to wed its drug delivery tech with Chugai's antibody assets in rare disease.

The FDA made waves in early September when it announced a plan to publicly release complete response letters, or CRLs, at the same time they are issued to sponsoring companies. What risks and opportunities does this new policy pose for biopharma companies?

Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.

In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx, with a thirty year track record in biopharma investing. The post Biotech royalty deals on the rise and here to stay appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

The FDA’s cancellation of a meeting to discuss the next steps in a R&D program has prompted Kezar Life Sciences to prepare to lay off staff and explore strategic alternatives.

The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.

Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma.

Just a few months after surfacing at Orca Bio following his early 2025 departure from Legend Biotech, Steve Gavel has taken on the chief commercial officer role at yet another cell therapy biotech. He is now CCO at Cabaletta Bio, effective immediately, where he brings a wealth of cell therapy experience.

The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.

French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.

Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.

University of Michigan spinout Evoq Therapeutics has struck its third major partnership with a biopharma powerhouse, signing on with Sanofi in a deal worth up to $500 million. The agreement comes after Evoq entered deals with Gilead Sciences in 2023 and Amgen in 2021.

AstraZeneca has returned to its longtime AI partner Immunai with a new deal worth up to $85 million to advance a target for a new inflammatory bowel disease therapy.

As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.

As the biotech industry in Luxembourg gradually grows, let us take a look at five biotech companies that are flourishing in the field. The post Biotech in Luxembourg: five companies that have made their name appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Boehringer Ingelheim will pay AimedBio up to $991 million to license and develop one of the South Korean biotech’s antibody-drug conjugates across a “broad range of cancers." The ADC asset girding the deal targets a protein expressed in many malignancies that plays a “significant role” in tumor growth, metastasis and therapeutic resistance, the partners said.

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for peptides? The post The advent of AI for peptide design: An emerging field appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir compared to standard-of-care treatments in healing lesions of immunocompromised patients with refractory HSV infections. The study paves the way for an FDA new drug application, the German company said on Wednesday.

The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. The post Prader Willi syndrome: five much-anticipated therapies poised for approval   appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so special. The post Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships. The post Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

As Asabys Partners has rolled Aliath Bioventures into its platform, it's worth asking if European biotech VCs are under pressure to scale. The post Are European biotech VCs under pressure to scale? Time to get pragmatic  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover the top biotech deals of September 2025, as four billion-dollar acquisitions took place and several licensing deals were signed. The post Top biotech deals in September 2025  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Here are six mRNA biotechs that have raised funds in recent years to push their candidates ahead through preclinical and clinical trials. The post Six companies leading the mRNA revolution in biotechnology appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). The post AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain  appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source

The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source

Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source

The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source

Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source

Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source

Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source

The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source

Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source

The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source

Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source

Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source

Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source

Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source

The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source

Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source

Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source

The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source

The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

With significant growth in activities globally, our /local page has strained to keep up and simply is not a great...